Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sun Pharmaceuticals Industries's quarterly market cap
increased
from Dec. 2025 (₹4,126,136 Mil) to Mar. 2026 (₹4,216,111 Mil) and
increased
from Mar. 2026 (₹4,216,111 Mil) to Jun. 2026 (₹4,468,761 Mil).
Sun Pharmaceuticals Industries's annual market cap
increased
from Mar. 2024 (₹3,888,242 Mil) to Mar. 2025 (₹4,162,126 Mil) and
increased
from Mar. 2025 (₹4,162,126 Mil) to Mar. 2026 (₹4,216,111 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sun Pharmaceuticals Industries's Enterprise Value for Today is ₹4,276,050 Mil.
Sun Pharmaceuticals Industries (NSE:SUNPHARMA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sun Pharmaceuticals Industries Market Cap Related Terms
Sun Pharmaceuticals Industries Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharmaceuticals Industries's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharmaceuticals Industries Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharmaceuticals Industries's Market Cap distribution charts can be found below:
* The bar in red indicates where Sun Pharmaceuticals Industries's Market Cap falls into.
Sun Pharmaceuticals Industries Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharmaceuticals Industries (NSE:SUNPHARMA) has a Market Cap of ₹4,564,495 Mil as of Aug. 22, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sun Pharmaceuticals Industries and its competitors. According to the industry distribution chart, Sun Pharmaceuticals Industries ranks #20 out of 1021 companies in the Drug Manufacturers industry, placing it in the top 2%.
Is Sun Pharmaceuticals Industries' Market Cap too high?
Sun Pharmaceuticals Industries' current Market Cap is ₹4,564,495 Mil. Based on the distribution chart, Sun Pharmaceuticals Industries ranks #20 out of 1021 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sun Pharmaceuticals Industries has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharmaceuticals Industries' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharmaceuticals Industries ranks #20 out of 1021 companies for Market Cap. This places Sun Pharmaceuticals Industries in the top 2% of its industry — outperforming the majority of peers. The industry median Market Cap is 235.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 235.54, based on 1,021 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sun Pharmaceuticals Industries and its competitors. For the Drug Manufacturers industry, the median Market Cap is 235.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharmaceuticals Industries's current Market Cap is ₹4,564,495 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharmaceuticals Industries stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries (NSE:SUNPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,954.66, compared to a current price of ₹1,902.40 — trading 2.7% below its estimated fair value. The current Market Cap is ₹4,564,495 Mil. Sun Pharmaceuticals Industries' overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sun Pharmaceuticals Industries (NSE:SUNPHARMA), the current Market Cap is ₹4,564,495 Mil as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharmaceuticals Industries (NSE:SUNPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries stock appears to be undervalued.
The current stock price of ₹1,902.40 is trading 2.7% below its estimated GF Value™ of ₹1,954.66.
GuruFocus considers Sun Pharmaceuticals Industries to be Fairly Valued.
Key valuation signals for NSE:SUNPHARMA:
Market Cap: ₹4,564,495 Mil
GF Value™: ₹1,954.66 vs. price of ₹1,902.40 (2.7% below fair value)
No single metric tells the full story. See the NSE:SUNPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharmaceuticals Industries Ltd is India's generic pharmaceutical manufacturing company. The company's substantial markets are the U.S. and India to make up the majority of revenue. The remaining is spread across both emerging and developed markets. In addition to generics, the company also produces and distributes name-brand formulas to specific geographies. It maintains manufacturing and research and development facilities globally to serve its markets but is majorly based in India.
92GF Score
Get the complete analysis for NSE:SUNPHARMA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUNPHARMA has been successfully added to your 
